National Institutes of Health: Pancreatic Neoplasms trials

The registry lists 117 Pancreatic Neoplasms studies with National Institutes of Health as lead sponsor. 14 are open to participants now and 37 have results posted.

Early Phase 1 1Phase 1 59Phase 2 62Phase 3 2No phase 8(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07619521Phase 1/2
• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 1
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
• Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by invitationNCT05600933
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingNCT05372614Phase 1
• Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid TumorsRecruitingNCT05053971Phase 1/2
• Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsRecruitingNCT04222413Phase 1
• Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsRecruitingNCT04074135Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsRecruitingNCT03190941Phase 1/2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
• Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruitingNCT01915225
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid TumorsActive, not recruitingNCT04616534Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerActive, not recruitingNCT04514497Phase 1Results posted
• Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas CancerTerminatedNCT04327986Phase 1/2Results posted
• Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompletedNCT03801915Phase 2Results posted
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results posted
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsTerminatedNCT03745326Phase 1/2Results posted
• M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the PancreasTerminatedNCT03451773Phase 1/2Results posted
• Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R MutationsCompletedNCT03040986Phase 2Results posted
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT02890355Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompletedNCT02810418Phase 1/2Results posted
• Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerCompletedNCT02311361Phase 1/2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02194829Phase 1/2Results posted
• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyCompletedNCT01658943Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT01585805Phase 2Results posted
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic CancerTerminatedNCT01583686Phase 1/2Results posted
• Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal CancersTerminatedNCT01445327Results posted
• SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaCompletedNCT01362790Phase 1/2Results posted
• Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP TrialCompletedNCT01294358Phase 1Results posted
• Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedNCT01280058Phase 2Results posted
• Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas CancerCompletedNCT01232829Phase 2Results posted
• Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01222689Phase 2Results posted
• Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic CancerCompletedNCT01195415Phase 2Results posted
• Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedNCT01064622Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerCompletedNCT00735917Phase 2Results posted
• S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00617708Phase 1/2Results posted
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic CancerCompletedNCT00577889Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryTerminatedNCT00482625Phase 2Results posted
• Dasatinib in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00474812Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic CancerTerminatedNCT00416793Phase 2Results posted
• Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer PatientsCompletedNCT00383760Phase 2Results posted
• Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic CancerCompletedNCT00331682Phase 2Results posted
• Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By SurgeryCompletedNCT00305877Phase 2Results posted
• Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00114244Phase 2Results posted
• Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic CancerCompletedNCT00091026Phase 2Results posted
• Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic CancerCompletedNCT00031694Phase 2Results posted
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerSuspendedNCT05685602Phase 1
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerSuspendedNCT04172532Phase 1/2
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02595931Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01783171Phase 1
• Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT01660971Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• TKM 080301 for Primary or Secondary Liver CancerCompletedNCT01437007Phase 1
• CT-011 and p53 Genetic Vaccine for Advanced Solid TumorsWithdrawnNCT01386502Phase 1
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• RO4929097 Before Surgery in Treating Patients With Pancreatic CancerTerminatedNCT01192763Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01145456Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyCompletedNCT00892736Phase 1
• GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryActive, not recruitingNCT00878163Phase 1
• Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract CancerCompletedNCT00559598
• Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic CancerCompletedNCT00547612Phase 1
• Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid TumorsCompletedNCT00462553Phase 1
• Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerCompletedNCT00436410Early Phase 1
• Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With GemcitabineCompletedNCT00397787Phase 2
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00288093Phase 1
• Randomized Trial of EUS Neurolysis in Pancreas CancerCompletedNCT00279292Phase 3
• Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic CancerWithdrawnNCT00253526Phase 2
• Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00114179Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Surgery for Pancreatic Tumors and Collection of Tumor Tissue for StudyTerminatedNCT00100321
• Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00096070Phase 2
• Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00095966Phase 2
• Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00088894Phase 3
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the PancreasCompletedNCT00085371Phase 2
• CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00075647Phase 2
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerCompletedNCT00063947Phase 1
• Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00052689Phase 2
• Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid TumorsTerminatedNCT00049608Phase 1
• Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00047307Phase 1
• UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic CancerCompletedNCT00039403Phase 1